Loading the procedure…
Loading the procedure…
Medicare volume, surgeons, state markets and device makers
Percutaneous liver, kidney, lung, and bone tumor ablation. Main billing specialty: interventional radiology.
Medicare fee-for-service tumor ablation cases in the 28 states summed: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 15% on average (83 state-years, 2020–2024): small markets swing, so treat it as rough.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| California | 8 | 940−1.6%/yr | −1.6%/yr | 0.30.9× | 0% | 1,020 in 2030+1.4%/yr |
| Florida | 3 | 795+1.4%/yr | +1.4%/yr | 0.41.1× | 0% | 1,250 in 2030+7.8%/yr |
| Texas | 6 | 772−0.3%/yr | −0.3%/yr | 0.41.1× | 0% | 1,010 in 2030+4.6%/yr |
| New York | 3 | 512+0.8%/yr | +0.8%/yr | 0.30.9× | 0% | 600 in 2030+2.7%/yr |
| Massachusetts | 4 | 431−1.7%/yr | −1.7%/yr | 0.51.4× | 0% | 590 in 2030+5.3%/yr |
| Pennsylvania | 3 | 418+0.9%/yr | +0.9%/yr | 0.31.0× | 0% | 330 in 2030−3.7%/yr |
| Minnesota | 7 | 358+1.3%/yr | +1.3%/yr | 0.82.5× | 0% | 500 in 2030+5.8%/yr |
| Illinois | 2 | 357+0.9%/yr | +0.9%/yr | 0.30.8× | 0% | 740 in 2030+13%/yr |
| Georgia | 2 | 335+1.7%/yr | +1.7%/yr | 0.41.2× | 0% | 260 in 2030−3.9%/yr |
| North Carolina | 3 | 334−1.9%/yr | −1.9%/yr | 0.31.1× | 0% | 320 in 2030−0.8%/yr |
| Virginia | 1 | 278+2.6%/yr | +2.6%/yr | 0.30.8× | 0% | 470 in 2030+9%/yr |
| Maryland | 5 | 276+7%/yr | +7%/yr | 0.31.0× | 0% | 670 in 2030+16%/yr |
| Arizona | 3 | 264+12%/yr | +12%/yr | 0.41.1× | 0% | 460 in 2030+9.6%/yr |
| Ohio | 1 | 253−4.9%/yr | −4.9%/yr | 0.20.7× | 0% | 520 in 2030+13%/yr |
| Missouri | 1 | 251−2.1%/yr | −2.1%/yr | 0.41.3× | 0% | 510 in 2030+12%/yr |
| Wisconsin | 3 | 239−0.5%/yr | −0.5%/yr | 0.41.3× | 0% | 180 in 2030−5%/yr |
| Michigan | 0 | 228−3.3%/yr | −3.3%/yr | 0.30.9× | 0% | 370 in 2030+8.4%/yr |
| South Carolina | 2 | 220−0.1%/yr | −0.1%/yr | 0.31.0× | 0% | 260 in 2030+3.1%/yr |
| Tennessee | 3 | 213+0.5%/yr | +0.5%/yr | 0.31.0× | 0% | 280 in 2030+4.6%/yr |
| Utah | 1 | 173+29%/yr | +29%/yr | 0.82.5× | 79% | 280 in 2030+8.3%/yr |
| Washington | 0 | 149−4.5%/yr | −4.5%/yr | 0.20.6× | 0% | 40 in 2030−20%/yr |
| Indiana | 0 | 141+2.6%/yr | +2.6%/yr | 0.20.6× | 0% | 190 in 2030+5.5%/yr |
| Kansas | 2 | 1340%/yr | 0%/yr | 0.31.0× | 0% | 320 in 2030+15%/yr |
| Colorado | 0 | 122−2.6%/yr | −2.6%/yr | 0.30.8× | 0% | 150 in 2030+3.4%/yr |
| Oregon | 0 | 120+0.7%/yr | +0.7%/yr | 0.30.9× | 0% | 140 in 2030+2.7%/yr |
| Louisiana | 0 | 112+4%/yr | +4%/yr | 0.30.9× | 0% | 290 in 2030+17%/yr |
| Alabama | 0 | 110+2.3%/yr | +2.3%/yr | 0.30.8× | 0% | 140 in 2030+4.6%/yr |
| New Jersey | 0 | 107−1.1%/yr | −1.1%/yr | 0.10.3× | 0% | 120 in 2030+1.8%/yr |
Professional codes (what the surgeon bills): CPT 47382, 47383, 50592, 50593, 32998, 20982, 20983.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed, summed over the states listed: states MedaRep covers where the procedure tops 100 Medicare cases a year. All Medicare adds Medicare Advantage patients at each state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. How the numbers are made · Data sources
In the last 10 years FDA made 118 decisions (510(k) clearances, De Novo grants, PMA approvals and supplements) under this category’s product codes, held by 52 companies. The most active:
| Company | Decisions, 10 years |
|---|---|
| Cryoconcepts | 8 |
| Recensmedical | 6 |
| Angiodynamics | 5 |
| Cryosurgery | 5 |
| Csa Medical | 5 |
| Galil Medical | 5 |
| Neuwave Medical | 5 |
| Varian Medical Systems | 5 |
| Boston Scientific | 4 |
| Creo Medical | 4 |
| Emblation | 4 |
| Medtronic | 4 |
Product codes: GEH (unit, cryosurgical, accessories), NEY (system, ablation, microwave and accessories). A company whose devices for this procedure are filed under other codes is not counted, and a PMA supplement counts as a decision of its own. Applicants are rolled up to their parent company.
The competitive landscape: each company scored on innovation pace, recall and report signals, commercial momentum and financial capacity.
The 10 busiest do 100% of the cases CMS names in California; 6 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
| Procedure | Surgeons | Medicare FFS | Growth since 2019 | Forecast |
|---|---|---|---|---|
| Breast biopsy & localization | 3,675 | 218,500−1.8%/yr | −1.8%/yr | 243,500 in 2030+1.8%/yr |
| Tumor & fibroid embolization | 314 | 18,000+6%/yr | +6%/yr | 42,100 in 2030+15%/yr |
Every procedure · Markets by state · Device companies · Compare two states
In 2025, 27 companies reported engagement with surgeons in the covered states worth $12M in consulting, speaking, meals and travel tied to these products, about $198K per surgeon billing it. Royalties are left out.
FDA, last 12 months: 11 clearances and approvals in the category, 5 recalled product lines (3 Class I). A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the state rankings. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.